Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

被引:43
作者
Seelig, AS [1 ]
Al-Hasani, S [1 ]
Katalinic, A [1 ]
Schöpper, B [1 ]
Sturm, R [1 ]
Diedrich, K [1 ]
Ludwig, M [1 ]
机构
[1] Univ Clin Hosp, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
关键词
cetrorelix; cryopreservation; GnRH agonist; GnRH antagonist; open freezing system;
D O I
10.1016/S0015-0282(01)03008-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the pregnancy rates of frozen-thawed 2-pronucleate (2PN) oocytes obtained either in a long protocol or in an antagonist protocol and ovarian stimulation with either human menopausal gonadotropin (hMG) or recombinant follicular stimulating hormone (recFSH). Design: Retrospective data analysis. Setting: Academic infertility center. Patient(s): Three hundred forty-two infertile couples who under-went a transfer of cryopreserved 2PN oocytes. Intervention(s): hMG (n = 194) or recFSH (n = 92) in a long protocol or hMG (n = 16) or recFSH (n = 40) stimulation under pituitary suppression with the GnRH antagonist Cetrotide was used. The 2PN oocytes were transferred after endometrial preparation using E, valerate and vaginal progesterone (Crinone 8% vaginal gel). Main Outcome Measure(s): Implantation, pregnancy, and abortion rates. Result(s): Implantation rates in the freeze-thaw cycles were 5.6% (hMG) and 3.8% (recFSH) with 2PN oocytes from the long protocol and 7% from the antagonist cycles, irrespective of whether hMG or reeFSH was used. Pregnancy rates were similar independent of whether they resulted from the long-protocol cycles with hMG (15.4%) and recFSH (13.1%) or from the antagonist protocol cycles with hMG (25.0%) and recFSH ( 17.5%. Conclusion(s): The potential to implant is independent of the gonadotropin-releasing hormone analogue and gonadotropin chosen for the collection cycle when previously cryopreserved 2PN oocytes were replaced after thawing in the cleavage stage. (Fertil Steril(R) 2002:77:472-5. (C)2002 by American Society for Reproductive Medicine.).
引用
收藏
页码:472 / 475
页数:4
相关论文
共 50 条
  • [41] Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study
    Bodri, Daniel
    Guillen, Juan Jose
    Galindo, Anna
    Mataro, Daniel
    Pujol, Aida
    Coll, Oriol
    FERTILITY AND STERILITY, 2009, 91 (02) : 365 - 371
  • [42] In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle
    Kummer, Nicole E.
    Weitzman, Vanessa N.
    Benadiva, Claudio A.
    Schmidt, David W.
    Engmann, Lawrence L.
    Nulsen, John C.
    FERTILITY AND STERILITY, 2011, 95 (08) : 2592 - 2594
  • [43] The LH endocrine profile in gonadotropin-releasing hormone analogue cycles
    Janssens, Lara
    Roelant, Ella
    De Neubourg, Diane
    GYNECOLOGICAL ENDOCRINOLOGY, 2022, 38 (10) : 831 - 839
  • [44] Gonadotropin-Releasing Hormone Agonists and Bone Density in Congenital Adrenal Hyperplasia: A Call for Further Research
    Bakhtiani, Priyanka
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (06) : e1458 - e1459
  • [45] Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus
    Kado, Ruba
    McCune, W. Joseph
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2020, 64 : 97 - 106
  • [46] The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention
    Schindler, Adolf E.
    GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (12) : 765 - 767
  • [47] Ovarian stimulation in in vitro fertilization with or without the "long" gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome
    Beloosesky, R
    Kol, S
    Lightman, A
    Itskovitz-Eldor, J
    FERTILITY AND STERILITY, 2000, 74 (01) : 166 - 168
  • [48] Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons
    Dolmans, Marie-Madeleine
    Taylor, Hugh S.
    Rodriguez-Wallberg, Kenny A.
    Blumenfeld, Zeev
    Lambertini, Matteo
    von Wolff, Michael
    Donnez, Jacques
    FERTILITY AND STERILITY, 2020, 114 (04) : 725 - 738
  • [49] Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle
    Kahraman, Korhan
    Berker, Bulent
    Atabekoglu, Cem Somer
    Sonmezer, Murat
    Cetinkaya, Esra
    Aytac, Rusen
    Satiroglu, Hakan
    FERTILITY AND STERILITY, 2009, 91 (06) : 2437 - 2444
  • [50] Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
    Halim, Binarwan
    Lubis, Hilma Putri
    OBSTETRICS & GYNECOLOGY SCIENCE, 2022, 65 (02) : 207 - 214